Hi-Tech Loses Motion And Now Awaits FDA Decision

Law360, New York (October 14, 2008, 12:00 AM EDT) -- A federal judge has rejected Hi-Tech Pharmacal Co. Inc.'s motion for a preliminary injunction that would have prevented other drugmakers from marketing a generic version of the glaucoma drug Cosopt until after the company completed its 180 days of market exclusivity.

Hi-Tech had argued that the U.S. Food and Drug Administration must be forced to withhold approval to other generics makers in order to preserve Hi-Tech's exclusivity rights under the Hatch-Waxman Act.

But in an opinion filed Friday, Judge John D. Bates of the U.S. District...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.